Baird Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $154
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Joel Beatty maintains an Outperform rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) but lowers the price target from $160 to $154.
August 01, 2024 | 11:55 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Baird analyst Joel Beatty maintains an Outperform rating on Jazz Pharmaceuticals but lowers the price target from $160 to $154.
The Outperform rating suggests continued confidence in Jazz Pharmaceuticals' performance, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100